- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | Inhibikase Therapeutics GAAP EPS of -$0.11 in-line | 1 | Seeking Alpha | ||
| 11.08. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.08. | Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity | 144 | GlobeNewswire (Europe) | WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily... ► Artikel lesen | |
| 23.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.07. | Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH | 275 | GlobeNewswire (Europe) | WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 14.07. | Inhibikase sells $50M of common stock to RA Capital | 1 | Seeking Alpha | ||
| 14.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility | 313 | GlobeNewswire (Europe) | WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 02.07. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 | 3 | Investing.com | ||
| 12.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | 249 | GlobeNewswire (Europe) | WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 08.04. | H.C. Wainwright reiterates Inhibikase stock rating on trial progress | 2 | Investing.com | ||
| 07.04. | Inhibikase: Erster Patient in Phase-3-Studie für Lungenhochdruck-Medikament aufgenommen | 3 | Investing.com Deutsch | ||
| 07.04. | Inhibikase startet Phase-3-Studie für Lungenhochdruck-Medikament mit erstem Patienten | 6 | Investing.com Deutsch | ||
| 07.04. | Inhibikase enrolls first patient in Phase 3 PAH drug trial | 1 | Investing.com | ||
| 07.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 227,00 | -0,39 % | Warum Eli Lilly 3,8 Milliarden US-Dollar auf Psychedelika setzt - und Emyria plötzlich an einem entscheidenden Engpass sitzt | ||
| TEVA | 31,800 | -0,93 % | 21% weniger Tics in einer Phase-IIa-Studie: Während Teva bei Tourette voranschreitet, startet NeuroThera Phase IIb in Deutschland | ||
| EYEPOINT | 4,860 | -10,83 % | XFRA PV3B: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEYEPOINT INC. DL-... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,032 | -2,46 % | Organigram Global Inc.: Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure | Leadership, operations and market development aligned across a global platform connecting Canada with Germany and other priority international markets
Sanity Group integration marks the next... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,974 | +0,81 % | Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial | TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 62,98 | -3,32 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| AMARIN | 11,900 | -3,25 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 211,50 | -2,08 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio | Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy
Leverages Jazz development expertise and commercial strength in... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,700 | -1,68 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 459,70 | -0,67 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Second-quarter 2026 Rezdiffra- (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,876 | +8,70 % | XORTX Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| BRIDGEBIO PHARMA | 71,40 | -0,68 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base | - The transaction supports the evolution of the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.... ► Artikel lesen | |
| OPUS GENETICS | 3,540 | +1,14 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SAVARA | 4,670 | -2,55 % | Savara Inc.: Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | -- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI's Proprietary eFlow Nebulizer System... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 40,000 | -0,45 % | Rigel Pharmaceuticals, Inc.: Rigel Reports Second Quarter 2026 Financial Results | Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 2,365 Euro und damit -3,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.